Citations 13

Effectiveness and Safety of Plasmapheresis in MOGAD Attacks

Neurology | July 22, 2026 | Volume: 107 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000218300 | PMID 42485605

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab to Prevent Relapses in Neuromyelitis Optica Spectrum Disorder (NMOSD) (P3-1.001)

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217044

Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients (S13.003)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s13.003

Epidemiology of Aquaporin-4 Autoimmunity and Neuromyelitis Optica Spectrum: A Comparison of Two Ethnically Divergent Populations (P3.003)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p3.003

Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrum

Annals of Neurology | February 18, 2016 | Volume: 79 | Issue: 5 | Pages: 775-783

10.1002/ana.24617 | PMID 26891082

ObjectiveNeuromyelitis optica (NMO) and its spectrum disorders (NMOSD) are inflammatory demyelinating diseases (IDDs) with a specific biomarker, aquaporin‐4–immunoglobulin G (AQP4‐IgG). Prior NMO/NMOSD epidemiological studies have been limited by lack of AQP4‐IgG seroprevalence assessment, absence of population‐based USA studies, and under‐representation of blacks. To overcome these limitations, we sought to compare NMO/NMOSD seroepidemiology across 2 ethnically divergent populations.MethodsWe performed a population‐based comparative study of the incidence (2003–2011) and prevalence (on December 31, 2011) of NMO/NMOSD and AQP4‐IgG seroincidence and seroprevalence (sera collected in 80–84% of IDD cases) among patients with IDD diagnosis in Olmsted County, Minnesota (82% white [Caucasian]) and Martinique (90% black [Afro‐Caribbean]). AQP4‐IgG was measured by M1 isoform fluorescence‐activated cell‐sorting assays.ResultsThe age‐ and sex‐adjusted incidence (7.3 vs 0.7/1,000,000 person‐years [p < 0.01]) and prevalence (10 vs 3.9/100,000 [p = 0.01]) in Martinique exceeded that in Olmsted County. The AQP4‐IgG age‐ and sex‐adjusted seroincidence (6.5 vs 0.7/1,000,000 person‐years [p < 0.01]) and seroprevalence (7.9 vs 3.3/100,000 [p = 0.04]) were also higher in Martinique than Olmsted County. The ethnicity‐specific prevalence was similar in Martinique and Olmsted County: 11.5 and 13/100,000 in blacks, and 6.1 and 4.0/100,000 in whites, respectively. NMO/NMOSD represented a higher proportion of IDD cases in Martinique than Olmsted County (16% vs 1.4%; p < 0.01). The onset age (median = 35–37 years) and female:male distribution (5–9:1) were similar across both populations; 60% of prevalent cases were either blind in 1 eye, dependent on a gait aid, or both.InterpretationThis study reports the highest prevalence of NMO/NMOSD in any population (10/100,000 in Martinique), estimates it affects 16,000 to 17,000 in the USA (higher than previous predictions), and demonstrates it disproportionately affects blacks. Ann Neurol 2016;79:775–783
Posterior reversible encephalopathy syndrome is not associated with mutations in aquaporin-4

Neurology Genetics | August 27, 2015 | Volume: 1 | Issue: 2 | Pages: No page available

10.1212/nxg.0000000000000013 | PMID 27066556

Genetic analysis of aquaporin-4 in neuromyelitis optica

Neurology | September 8, 2011 | Volume: 77 | Issue: 12 | Pages: 1149-1155

10.1212/wnl.0b013e31822f045b | PMID 21900637

Azathioprine

Neurology | August 4, 2011 | Volume: 77 | Issue: 7 | Pages: 659-666

10.1212/wnl.0b013e31822a2780 | PMID 21813788

Paraneoplastic isolated myelopathy

Neurology | June 14, 2011 | Volume: 76 | Issue: 24 | Pages: 2089-2095

10.1212/wnl.0b013e31821f468f | PMID 21670438

Familial neuromyelitis optica

Neurology | July 26, 2010 | Volume: 75 | Issue: 4 | Pages: 310-315

10.1212/wnl.0b013e3181ea9f15 | PMID 20660861